Objective: Tenosynovial giant cell tumor (TGCT) is a rare benign proliferative and inflammatory disease arising from synovia of joints, bursae, or tendon sheaths. We aimed to estimate incidence rate and prevalence of TGCT in Denmark, to describe patient characteristics and treatment modalities among patients with TGCT, and to estimate risk of TGCT recurrence.
Methods: Using registry data on pathology examinations and inpatient and outpatient hospital diagnoses, we identified adult patients with diagnoses of diffuse TGCT (D-TGCT) or localized TGCT (L-TGCT) between 1997 and 2012, followed through 2012. We described patients' characteristics, treatment modalities, and recurrence.
Results: We identified 2087 patients with L-TGCT and 574 patients with D-TGCT. Their incidence rates per million person-years were 30.3 (95% CI 29.1-31.7) and 8.4 (95% CI 7.7-9.1), respectively. At the end of 2012, prevalence per 100,000 persons was 44.3 (95% CI 42.4-46.3) for L-TGCT and 11.5 (95% CI 10.6-12.6) for D-TGCT. Women made up 61% of the patients with L-TGCT and 51% of the patients with D-TGCT. Median age at diagnosis was 47 years. Ten-year risk of recurrence was 9.8% (95% CI 8.4-11.3%) after L-TGCT and 19.1% (95% CI 15.7-22.7%) after D-TGCT.
Conclusion: This study contributes evidence about epidemiology of TGCT based on routinely collected population-based data gathered in a setting of universal equal access to healthcare and complete followup.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.3899/jrheum.160816 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Treatment of Tenosynovial Giant Cell Tumor of the Cervical Spine with Postoperative Anti-RANKL Antibody (Denosumab) Administration.
Acta Med Okayama
December 2024
Department of Neurological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences.
Tenosynovial giant cell tumor (TGCT) is a fibrous histiocytic tumor originating in the synovial membrane. While cervical TGCT may not be considered a common diagnosis preoperatively because it is relatively rare, it has a high recurrence rate and should be considered. Total resection is preferable, but it can be challenging due to the risk of damaging the vertebral artery.
View Article and Find Full Text PDFEmerging therapeutics in the management of tenosynovial giant cell tumor (TGCT).
Expert Rev Anticancer Ther
December 2024
Department of Internal Medicine, Division of Hematology/Oncology, University of Michigan, Ann Arbor, MI, USA.
Article Synopsis
- Tenosynovial giant cell tumors (TGCTs) are aggressive tumors often found in younger individuals, leading to long-term disability and typically managed via surgery, which has its own risks.
- This review focuses on systemic treatment options, particularly for the diffuse subtype (DT-TGCT), and assesses recent advancements and the historical context of these therapies.
- Notable progress includes the development of CSF1 receptor-targeting therapies like pexidartinib, paving the way for further research on treatment effectiveness and optimizing patient outcomes.
Tenosynovitis with psammomatous calcifications: Series of 18 cases and review of the literature emphasizing a common source of expert consultation and updated differential diagnosis.
Virchows Arch
December 2024
Department of Pathology, The Johns Hopkins University School of Medicine, 401 N Broadway, Weinberg Building 2245, Baltimore, MD, 21231, USA.
Article Synopsis
- - Tenosynovitis with psammomatous calcifications (TPC) is a rare, non-cancerous condition that often affects women and is thought to result from repetitive use or trauma, commonly appearing at sites like the hands, feet, and wrists.
- - In a study involving 18 new cases, most patients presented with painful masses, and imaging often showed benign characteristics, but many of these cases were misdiagnosed as more serious conditions like gout or tumors.
- - Follow-up on patients (mostly for around 30 months) showed no local recurrences after surgical removal, highlighting the necessity for greater awareness among medical professionals regarding TPC.
Treatment of tenosynovial giant tumors with colony-stimulating factor 1 receptor kinase inhibitors: When to start? When to stop? When to restart?
Cancer
November 2024
Department of Medical Oncology, Léon Bérard Cancer Center, Lyon, France.
A phase 4, multicenter, global clinical study to evaluate discontinuation and rechallenge of pexidartinib in patients with tenosynovial giant cell tumor previously treated with pexidartinib.
Cancer
November 2024
Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Article Synopsis
- Pexidartinib is a drug used for treating tenosynovial giant cell tumor (TGCT) in patients where surgery isn't an option, and this study looked at the effects of stopping and then restarting the medication.
- It was a phase 4 global study involving patients who had benefited from pexidartinib, allowing them to either continue treatment or stop with the option to restart later, monitoring their tumor progression and quality of life.
- Results showed that while about 54.5% of patients who stopped the drug experienced disease progression, none of those who continued treatment saw their condition worsen over a 24-month period.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!